Carmel Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Carmel
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Carmel News
Carmel Valley family has loved ones living near bombing sites in Iran, hopes attacks lead to regime change
A Carmel Valley family with loved ones near Iran bombing sites says family members are fearful but hopeful for regime change.
Morning Bid: AI horror stories
By Anna Szymanski Feb 27 - Everything Mike Dolan and the ROI team are excited to read, watch and listen to over the weekend. From the Editor Hello Morning Bid readers! Markets were jittery this week, ...
Sophos and Spektrum Labs Partner to Launch Insurability Fastrack Program with Sophos MDR
Sophos, a global leader in innovative security solutions for defeating cyberattacks, and Spektrum Labs, the creator of the Fusion Platform for continuous cyber resilience validation, today announced a ...
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership
PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients ...